Last reviewed · How we verify
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Tolerability and Effect of MK0524A on Niacin-Induced Acute Flushing in Lipid Clinic Patients
The primary objective of the study is to assess the effects of MK0524A in reducing flushing associated with niacin.
Details
| Lead sponsor | Merck Sharp & Dohme LLC |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 330 |
| Start date | 2007-04 |
| Completion | 2007-08 |
Conditions
- Flushing
Interventions
- MK0524A, /Duration of Treatment : 4 Weeks
- Comparator : niacin /Duration of Treatment : 1 Weeks
Primary outcomes
- MK-0524A produces less flushing during the acute dosing period than niacin extended-release as measured by maximum Global Flushing Severity Score (GFSS) categorized as none/mild, moderate, severe, extreme. — Over 1 week